J. D. de Jong

发表

Genomic Subtyping in Bladder Cancer

E. Gibb, T. Jalanko, J. D. de Jong, 2020, Current Urology Reports.

Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis

Mauro A. A. Castro, A. G. Robertson, Y. Lotan, 2019, Genome Medicine.

A Urine-Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.

E. Steyerberg, K. V. van Kessel, E. Zwarthoff, 2020, The Journal of urology.

Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

S. Sleijfer, H. V. van Melick, D. Somford, 2022, ESMO open.

Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography

S. Klein, W. Niessen, H. V. van Melick, 2022, Journal of personalized medicine.

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients

J. D. de Jong, H. Mostafid, J. Boormans, 2018, Bladder cancer.

T1-Substaging of Non-muscle Invasive Bladder Cancer is Associated with BCG-Failure and Improves Patient Stratification at Diagnosis.

E. Zwarthoff, J. D. de Jong, J. Boormans, 2020, The Journal of urology.

Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.

Henry W. Long, M. Albà, J. Bellmunt, 2022, British journal of cancer.

Concordance of PD‐L1 expression in matched urothelial bladder cancer specimens

D. Nieboer, H. Stoop, J. D. de Jong, 2018, Histopathology.

Reply by Authors.

Y. Lotan, S. Boorjian, T. Wheeler, 2020, The Journal of urology.

Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.

J. D. de Jong, H. Mostafid, J. Boormans, 2021, Urologic oncology.

Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.

F. Montorsi, A. Salonia, N. Fossati, 2020, European urology oncology.

Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.

A. Wyatt, E. Davicioni, M. Annala, 2019, Urologic oncology.

Molecular and clinical heterogeneity within the luminal subtype

E. Zwarthoff, J. D. de Jong, 2019, Nature Reviews Urology.

Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis

Henry W. Long, M. Albà, J. Bellmunt, 2022, British Journal of Cancer.

Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.

U. Capitanio, F. Montorsi, A. Salonia, 2020, European urology.

Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy

Y. Lotan, S. Boorjian, E. Davicioni, 2021, The Journal of urology.

Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.

A. Wyatt, E. Davicioni, M. Annala, 2019, Urologic oncology.

Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.

U. Capitanio, F. Montorsi, Y. Lotan, 2021, European urology.

Biomarkers Predicting Outcomes Before and After Neoadjuvant Immune Checkpoint Inhibition Therapy for Muscle-Invasive Bladder Cancer

E. Gibb, J. D. de Jong, 2022, Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers.

PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays

H. Stoop, J. D. de Jong, J. Boormans, 2021, Virchows Archiv.

RNA-based urinary assays for non-muscle invasive bladder cancer

J. D. de Jong, J. Boormans, T. Zuiverloon, 2022, Current opinion in urology.

Re: A urine-based genomic assay to triage patients with hematuria for cystoscopy.

E. Zwarthoff, J. D. de Jong, 2020, The Journal of urology.

A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.

Y. Lotan, K. V. van Kessel, E. Zwarthoff, 2022, European urology oncology.

Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.

Y. Lotan, S. Boorjian, S. Shariat, 2020, The Journal of urology.

Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.

Y. Lotan, S. Boorjian, T. Wheeler, 2020, European urology oncology.

A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging.

Y. Lotan, S. Boorjian, T. Wheeler, 2020, The Journal of urology.

Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.

E. Gibb, J. D. de Jong, V. Narayan, 2021, American journal of clinical pathology.

Nation-wide progression outcomes after BCG therapy for high- and very high-risk T1 non-muscle invasive bladder cancer patients – A prospective registry study

K. Aben, J. Witjes, J. D. de Jong, 2023, European Urology.

Re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035

E. Gibb, J. D. de Jong, 2022, European Urology.

The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria: A Systematic Review from the European Association of Urology Guidelines Office.

Yuhong Yuan, J. D. de Jong, H. Mostafid, 2023, European Urology Focus.

Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.

Y. Lotan, E. Gibb, J. D. de Jong, 2024, Urologic oncology.

A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy

E. Zwarthoff, J. D. de Jong, T. Zuiverloon, 2024, European urology open science.